SecBot SecBot
PRESS-RELEASE ·Filed Sep 9, 2026

DGX

Quest Diagnostics
BULLISH
Impact 6/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The EPS beat is a positive signal, but the lack of a guidance raise or disclosed partnership revenue limits the upside.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$231.14
T+0 close · Sep 9, 2026 · via day close
Latest settled
−0.14%
T+20 · $230.81 · next T+60 in 18d
Vs SPY
−2.27%
α at T+20
Latest observation
+14.52%
T+46 · FF3 residual α
  1. T+0 · Sep 10 $231.14entry
  2. T+1 · 2mo ago +1.68%α +0.83% · $235.02
  3. T+5 · 2mo ago +7.06%α +7.56% · $247.45
  4. T+20 · 6w ago −0.14%α −2.27% · $230.81
  5. T+47 · todayOpen
  6. T+60 · in 18d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Quest Diagnostics reported Q2 2026 EPS of $3.12, a 9.0% beat vs the $2.86 consensus, and announced a partnership with Apple to offer lab testing through the Apple Health app. The EPS beat is notable, but the Apple Health integration is a long-term consumer growth catalyst with no immediate financial impact disclosed.

Key Financial Metrics

EPS
$3.12
est $2.86 · +9.1%
Rating
beat

Key Facts

  • Q2 2026 EPS of $3.12 beat consensus of $2.86 by 9.0%
  • Revenue not explicitly stated in the provided filing document; set to null
  • Announced partnership with Apple to offer a 50+ biomarker lab test panel via the Apple Health app later this year
  • The lab panel will be available for $119 at approximately 2,000 Quest patient service centers
  • No guidance change or revenue figures for the partnership were disclosed

Financial Impact

EPS beat of $0.26 per share vs consensus; partnership revenue potential undisclosed

epsrevenue

Risk Factors

  • No guidance raise was provided, which may cap the stock's upside
  • The Apple Health partnership has no disclosed revenue or margin impact, creating uncertainty about its materiality

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories
Analyst Consensus
57% bullish (23 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302874147

Track record

24 reports on DGX

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +5.88% at T+20 after the Jul 23, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
  2. Nov 12, 20263d ago Insider Cluster Neutral 2/10 Entry $259.60 Now $262.21 +1.01% settles Feb 11
  3. Nov 10, 20266d ago Press Release Neutral 2/10 Entry $258.69 Now $262.21 +1.36% settles Feb 9
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $258.44 Now $262.21 +1.46% settles Feb 8
  5. Nov 9, 20267d ago Press Release Neutral 2/10 Entry $259.67 Now $262.21 +0.98% settles Feb 5
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $259.67 Now $262.21 +0.98% settles Feb 5
  7. Nov 5, 202610d ago 3 Neutral 2/10 Entry $255.63 Now $262.21 +2.57% settles Feb 4
  8. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $247.06 Now $262.21 +6.13% settles Feb 1
  9. Nov 3, 202613d ago 144 Neutral 3/10 Entry $247.06 Now $262.21 +6.13% settles Feb 1
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $245.62 Now $262.21 +6.75% settles Jan 26
Showing 10 of 24

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 9, 2026